logo/base Created with Sketch.

New EASL Clinical Practice Guidelines Make Unprecedented Recommendation for Non-Invasive FibroScan® and Care Management

The release of new guidelines from the European Association for the Study of the Liver (EASL), a professional association for individuals researching liver disease, represent a significant advance for the non-invasive management of patients with liver diseases and an unprecedented level of recommendation for Echosens’ solutions.

Given EASL’s highly prescriptive recommendations for FibroScan® parameters, Echosens technologies are now positioned as the cornerstone of non-invasive tests (NIT) for the future of liver disease management—across the liver care continuum and all population groups.


Notable Recommendations

As the NIT of reference, FibroScan® combines standardization, clinical performance and accessibility for early patient identification, in first-line after Fib-4, either in primary care, diabetology clinic or liver clinic, and for advanced liver disease patient management, portal hypertension and hepatocellular carcinoma (HCC) risk stratification.


EASL guidelines highlights include:

> Liver stiffness measurement (LSM) by transient elastography (TE) received support from 13 “strong recommendations” and four other recommendations or supportive statements.

> Controlled attenuation parameter (CAP) is now mentioned in the guidelines, with clear cut-off for steatosis diagnosis.

> Spleen stiffness measurement (SSM) is now recommended as an additional NIT to further improve risk stratification and refine the risk of high-risk varices.


Covering Critical Conditions and All Populations

Across all population groups, FibroScan® garnered 18 recommendations or statements from the EASL guidelines, including for non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH), alcoholic liver disease (ALD), hepatitis C virus, including post sustained virologic response (PSVR), primary biliary cirrhosis (PBC)/primary sclerosing cholangitis (PSC) and autoimmune hepatitis (AIH).


FibroScan® was also recommended for at-risk populations, such as patients with metabolic risk factors and/or harmful use of alcohol. All recommended cut-off values are clearly specified for LSM by TE.


These guidelines further demonstrate the value of FibroScan® for comprehensive management of liver health in the battle against a global liver disease epidemic.

chevron Discover the guideline related to FibroScan®